Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
Completed · Phase 2 · NCT04318080
Conditions: Classical Hodgkin Lymphoma
At a glance
- Research payments reported, 2025
- $56,194
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 46
About the trial
- Sponsor
- BeiGene (with Lymphoma Study Association)
- Tested
- Tislelizumab (drug)
- Dates
- Started 2020-08-20; completion 2024-08-29
- Results posted
- Yes
This was a Phase 2 trial evaluating the effectiveness and safety of tislelizumab in participants with relapsed or hard-to-treat classical Hodgkin lymphoma (cHL). Participants were grouped by prior treatments. The main outcome was to assess overall response rate (ORR) across both cohorts. Participants continued receiving the study treatment until their disease got worse, side effects became too severe, or they chose to stop for other reasons.
From ClinicalTrials.gov, last updated 2025-09-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines Ltd. reported $56,194 in research payments for this study in 2025 (7 payments).
Products named: Tevimbra
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Dipenkumar K. Modi, M.D. Internal Medicine · Detroit, MI
- Harsh R. Shah, DO Hematology & Oncology · Detroit, MI
- Radhakrishnan Ramchandren, MD Hematology · West Reading, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.